Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked hard but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past few shares. My first CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview which I came away with a poor opinion of the business.

Irony of irony, the poor opinion of mine of the business enterprise has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the know-how and also linked intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) as well as the first brand new drug program approval ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it’s this individual treatment and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on the website of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple presentations and multiple publications.

Can it all be smoke and mirrors? That’s a question I’ve been asking myself with the very beginning of my interest in this particular company. Judging by the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *